Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paul Daruwala Insider Profile
4 Followers
Paul Daruwala, COO at Cidara Therapeutics, holds 221.10K shares in Cidara Therapeutics (Ticker: CDTX). Most recently, Paul Daruwala Sold $16,199 shares of Cidara Therapeutics on Sep 13, 2022 for an estimated value of 11.02K.
Profitable Transactions
2 out of 5 Profitable Transactions
Average Return
-4.10%
Average return per transaction
Time Frame
Compare to
Insider Roles
COO
Roles that Paul Daruwala holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Apr 05, 2021 - Apr 05, 2022
Return:+65.10%
The most profitable trade made by Paul Daruwala
Paul Daruwala's Trading History
List of latest transactions for each holding click on a transaction to see Paul Daruwala's performance on stock
You May Also Like
Paul Daruwala insider profile FAQ
What is the percentage of profitable transactions made by Paul Daruwala?
The percentage of profitable transactions made by Paul Daruwala is 40%.
What is the average return per transaction made by Paul Daruwala?
The average return per transaction made by Paul Daruwala is -4.10%.
What stocks does Paul Daruwala hold?
Paul Daruwala holds: CDTX stocks.
What was Paul Daruwala’s latest transaction?
Paul Daruwala latest transaction was an Informative Sell of $11.02K.
What was Paul Daruwala's most profitable transaction?
Paul Daruwala’s most profitable transaction was an Informative Sell of CDTX stock on April 5, 2021. The return on the trade was 65.10%.
What is Paul Daruwala's role in Cidara Therapeutics?
Paul Daruwala's role in Cidara Therapeutics is COO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.